Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - The company experienced a significant rebound in its book-to-bill ratio, reaching 1.13x in Q3, indicating improved customer sentiment and demand in the biotech and large pharma sectors [1]. Group 1: Customer Sentiment and Leadership Transition - The company noted that Q2 was an anomaly due to customer hesitation linked to a CEO transition, which has since resolved more quickly than anticipated [3]. - Engagement with top customers and collaboration with the sales and executive teams contributed to alleviating concerns surrounding the leadership change [3][4].